RxDoctor Payments Data

Naresh Patel, MD

Family Medicine · Oxnard, CANPI 1750605721

Payments from drug & device makers

$258in general payments, 2019–2025

Across 8 payments — averaging $32.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$100
  • Johnson & Johnson$70
  • Lilly USA, LLC$27
  • Seqirus USA Inc$24
  • Pfizer$23
  • Amgen$14

What the payments were for

  • Food & beverage$258100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK2$100
Johnson & Johnson(2 entities)2$70
Lilly USA, LLC1$27
Seqirus USA Inc1$24
Pfizer1$23
Amgen1$14

How this compares

$258 in reported general payments places this provider in the 50th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$122,798
Medicare patients
163
Services billed
1,330

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide55$105,699
JardianceEmpagliflozin54$62,710
JanuviaSitagliptin Phosphate27$38,449
FarxigaDapagliflozin Propanediol36$37,040
TrulicityDulaglutide22$28,556
EntrestoSacubitril/Valsartan16$22,303
OzempicSemaglutide14$18,767
TradjentaLinagliptin19$16,968
XareltoRivaroxaban11$15,934
Tresiba Flextouch U-100Insulin Degludec30$14,004
MyrbetriqMirabegron12$10,868
LinzessLinaclotide11$6,934
Celecoxib96$4,563
Lantus SolostarInsulin Glargine,hum.Rec.Anlog39$3,885
LantusInsulin Glargine,hum.Rec.Anlog29$3,201

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$27$28,55622 claims
Johnson & JohnsonXarelto$70$15,93411 claims
GSKArnuity Ellipta$100$2,87512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 10,533 family medicine providers in California.

Other family medicine in Oxnard

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →